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The current Asian H5N1 highly pathogenic avian influenza virus has spread over much of Asia and into Europe and Africa. As well as
affecting village and commercial chicken operations in many South East Asian countries, it differs from past H5 avian influenza viruses in that it
causes morbidity and mortalities in other domesticated birds, such as ducks and turkeys and in wild waterbirds. Effective vaccines that can prevent
infection, as well as disease, and be used in a variety of avian species are needed for field use. In this report, a bivalent H5N9+H7N1 oil emulsion
vaccine is compared, in ducks, to a monovalent H5N3 oil emulsion vaccine that has been derived by reverse genetics with an H5 from A/chicken/
Vietnam/C58/04. While both vaccines protected against morbidity, the monovalent vaccine provided effective protection, with no evidence of
shedding of the challenge virus and no serological response to the H5N1 challenge virus.
© 2006 Elsevier Inc. All rights reserved.Keywords: Avian influenza; H5N1; Vaccine; DucksIntroduction
The major control strategy for highly pathogenic avian
influenza (HPAI) outbreaks in poultry has traditionally been one
of eradication via movement restrictions and slaughter of
affected and at-risk birds and improved biosecurity at poultry
facilities to prevent initial infection. However, with the
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doi:10.1016/j.virol.2006.08.046poultry, including ducks and turkeys, and in wildlife species,
particularly migrating birds, alternate control strategies must be
considered, with vaccines likely to be a key component.
Currently available commercial vaccines for avian influenza
are oil emulsion, killed virus vaccines. They have mostly been
used to control endemic low pathogenic avian influenza (LPAI)
in chickens and turkeys, or HPAI outbreaks in Pakistan and
Mexico (Halvorson, 2002; Naeem, 1998; Swayne and Suarez,
2000). The European Union has approved use of inactivated oil
emulsion vaccines for use in Italy, provided they allow for
differentiation of infected versus vaccinated birds (Capua et al.,
2002). Control of mildly pathogenic avian influenza in Mexico
has been undertaken with both killed vaccines and recombinant
fowlpox vaccines (Swayne and Suarez, 2000).
While it has been demonstrated that an inactivated oil
emulsion vaccine could interrupt transmission of H7N7 (Van der
Goot et al., 2005) or the current H5N1 HPAI (Ellis et al., 2004),
concerns still exist that these vaccines may not have 100%
efficacy in the field and will not totally prevent shedding of
virus. Additionally, their use does not allow the differentiation
between infected and vaccinated birds, which interferes with
Table 1











Day 4b Day 7b
106.7 3 5 +/− nd/ndc nd
3 – +/− −/− 128
3 4 +/+ nd/nd nd
3d 4 +/+ nd/nd nd
3d 5 −/− nd/nd nd
105.7 3d 4 +/− nd/nd nd
3 – −/− +/+ 128
3d 4 +/− nd/nd nd
3d 4 +/− nd/nd nd
3 8 +/− −/− nd
104.7 9 9 −/+ +/+ nd
9 9 −/− −/− nd
8 9 −/− +/+ nd
8 8 −/− +/− nd
7 8 −/− +/+ nd
103.7 6 6 −/− nd/nd nd
– – −/− +/− 8
10 10 −/− +/− nd
– – −/+ −/+ 64
10 10 −/− +/+ nd
102.7 – – −/− −/− <2
– – −/− −/− <2
– – −/− −/− <2
– – −/− −/− <2
– – −/− −/− <2
a Antibody titer on day 10 post challenge.
b Positive or negative for virus in the pharynx/cloaca.
c Not done.
d Nervous clinical signs observed in addition to depression.
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they been formulated or tested for vaccination efficacy in ducks.
Vaccines based on the current Asian H5N1 strain and which
overcome these problems and for use in a variety of poultry
species are needed urgently.
The Asian H5N1 virus cannot be grown to high titer in eggs,
which is the traditional method of virus production for human
and avian influenza vaccines. Thus, alternatives to homologous
virus vaccines are being developed. Live vectored vaccines can
provide additional safety and the ability to differentiate between
infected and vaccinated birds. Fowlpox (Qiao et al., 2003),
infectious laryngotracheitis virus (Luschow et al., 2001),
Newcastle disease virus (Park et al., 2006) and adenovirus
(Gao et al., 2006) vectors expressing the hemagglutinin, H5,
have all been assessed and shown to have protective efficacy,
with reduction, but not complete elimination, of virus shedding.
Other influenza strains, particularly those that share the H5
hemagglutinin type, but with a different neuraminidase, have
been shown to have some efficacy in the field (Ellis et al., 2004),
but the most promising approach is the use of reverse genetics to
create an influenza virus that has the current H5 in a genetic
background that allows growth to high titer in eggs, but has low
pathogenicity in either avian or mammalian species.
Reverse genetics has been used to create influenza virus
reassortants with the hemagglutinin and neuraminidase genes
from either the human H5N1 isolate, A/HK/491/97 (Subbarao et
al., 2003), or the avian H5N1 isolate, A/Goose/Guangdong/96
(Tian et al., 2005). Both these reassortants are apathogenic in
chickens and the reassortant virus with H5 and N1 from A/
Goose/Guangdong/96 has been tested as formalin inactivated
preparation for protective efficacy against the parent HPAI
H5N1 in specific pathogen-free (SPF) chickens, and in non-SPF
geese and ducks. Those studies demonstrated that the reassortant
vaccine could prevent mortality and reduce shedding of the
challenge virus.
Inclusion of a different neuraminidase subtype in the
reassortant vaccine allows differentiation of infected versus
vaccinated birds. This principle has been demonstrated with
reassortants using hemagglutinin genes from H5 and H7 LPAI
viruses and the remaining genes, including the N1 fromA/WSN/
33 (Lee et al., 2004). Oil emulsion vaccines with these
reassortants reduced replication of the parental H5 and H7
LPAI strains in SPF chickens. A reassortant virus with H5 from
A/Goose/Hong Kong/437-4/99 and N3 from A/Duck/Germany/
1215/73 has been constructed (Liu et al., 2003). When
formulated as an oil emulsion, the vaccine was able to protect
SPF chickens against mortality and markedly reduce virus
shedding following challenge with HPAI H5N1 virus but did not
provide sterilizing immunity. In this study a similar reassortment
virus where the hemagglutinin gene was derived from A/
chicken/Vietnam/C58/04 (H5N1) virus was used in an inacti-
vated oil emulsion formulation proprietary to Fort Dodge
Animal Health.
As ducks appear to be playing a critical role in the
amplification and spread of H5N1 influenza virus in Asia,
vaccines that are effective in ducks will provide an important
tool for control of the disease. The current study, reported here,compares, in ducks, the efficacy of the H5N3 reassortant virus
vaccine to that of a bivalent H5N9+H7N1 vaccine and
demonstrates that the reassortant virus provides superior
protection, with no evidence of shedding of the challenge
virus on days 4 and 7 post challenge and no antibody response to
the challenge virus, indicating little, if any, viral replication.
Results
Pathogenicity of A/Muscovy/Vietnam/453/2004 in ducks
Allantoic fluid from SPF eggs infected with the H5N1 strain,
A/Muscovy duck/Vietnam/453/2004, was diluted in ten-fold
steps in PBS and used to infect groups of five ducks. The virus
was administered intraocularly, intranasally and orally, each
bird receiving from 102.7 to 106.7 EID50 of virus. Mortality,
morbidity, virus re-isolation and antibody levels were measured
over the dose range (Table 1). Four out of five birds died in each
of the two highest dose groups (106.7 and105.7 EID50); all birds
died at the 104.7 EID50 dose; three of five at the next lowest dose
and all birds survived the lowest dose of 102.7 EID50. The
development of morbidity was delayed in the lower doses and
the time to death was also longer in the lower doses. The
observed clinical signs of morbidity were reduced food intake,
reduced water and grooming activity and nervous signs. The
nervous signs (head waving, high-stepping gait, falling and
Table 3
Virus isolation following challenge of vaccinated ducks




Day 4 Day 7 Day 4 Day 7 Day 4 Day 7
+/+ a −/− +/+ −/− −/− −/−
+/− −/− +/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
+/+ Dead −/− −/− −/− −/−
−/− +/− −/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
+/− −/− −/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
−/− +/− −/− −/− −/− −/−
+/− −/− −/− −/− −/− −/−
+/− +/− −/− −/− −/− −/−
+/− Dead −/− −/− −/− −/−
−/− −/− −/− −/−
a Virus isolation from pharynx/cloaca.
Table 4
Antibody titers following challenge of vaccinated ducks









Day −1 Day 11 Day 14 Day −1 Day 11 Day 14
<4 b 32 128 <4 64 128 16 8 8
<4 – – <4 32 32 32 32 16
<4 – – <4 64 64 32 64 32
<4 – – <4 <4 16 8 16 16
<4 – – <4 <4 32 32 32 16
<4 – – <4 4 32 32 32 16
<4 256 128 <4 32 32 32 16 8
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dose groups and only during disturbance of the birds.
Swabs were taken from the pharynx and cloaca on days 4
and 7 after challenge. Virus was not isolated from birds in the
lowest dose group, but was isolated from one or more samples
from most birds in the other groups. Virus was not detected in
three birds that received between 103.7 and 106.7 EID50, but all
of those birds displayed clinical signs and died, indicating that
there was likely to have been virus replication. Antibody was
detected at day 10 in surviving birds from the four highest dose
groups. There was no antibody in the birds in the lowest dose
group.
For the purpose of calculation of a challenge dose for vaccine
trials, an infected bird was defined as exhibiting clinical signs
(including mortality) and/or virus detection in pharyngeal or
cloacal swabs on day 4 or 7 post challenge, or seroconversion in
survivors. Using the Karber formula, the dose of 104.7 EID50
was calculated as 101.5 duck infectious doses50 (DID50) and this
dose was used in the following vaccination trial.
Protective efficacy of the bivalent and monovalent vaccines
Ducks were vaccinated with the inactivated bivalent vaccine
(H5N9 plus H7N1) or the monovalent vaccine (H5N3) at 1 day
old and 3 weeks old, or left unvaccinated. Three weeks after the
second vaccination all groups were challenged with A/Muscovy
duck/Vietnam/453/2004 (H5N1). By day 4 following challenge,
all the unvaccinated birds had become inappetant, with green
diarrhea and apparent weight loss. All birds in the two
vaccinated groups remained clinically well throughout the
study period (data not shown). Nine out of fourteen (64%) of the
unvaccinated birds died following challenge and none of the
vaccinated birds died (Table 2). Challenge virus was re-isolated
from all birds in the unvaccinated group, from two birds in the
bivalent vaccine group and from none of the birds that received
the monovalent H5N3 vaccine (Table 3).
Antibody titers following vaccination and challenge of ducks
Hemagglutination inhibiting (HI) antibody titers were
assayed on the day prior to challenge with H5N1 virus and on
days 11 and 14 after challenge. Antigen from A/Muscovy duck/
Vietnam/453/2004 was used for the assays. Prior to challenge,
no antibody was detected in birds in the unvaccinated group.
Low HI titers (4 to 8) were detected in the bivalent vaccine
group, which were exposed to a heterologous H5 and H7, and
higher titers (between 8 and 64) in the groups that received the
monovalent vaccine with H5 from A/Chicken/Vietnam/C58/04Table 2
Mortality following challenge a with A/Muscovy duck/Vietnam/453/2004
(H5N1)
Vaccine Nil Bivalent (H5N9+H7N1) Monovalent (H5N3)
Dead/Total ducks 9/14 0/15 0/15
a Ducks were vaccinated at 1 day old and 3 weeks old and challenged with
101.5 DID50 virus at 6 weeks of age.(Table 4). On days 11 and 14, most of the unvaccinated ducks
had already died, but those remaining had antibody titers in the
range of 32 to 256. In ducks receiving the bivalent vaccine,
antibody was detectable at titers between 32 and 128 on day 14,
but on day 11 the titers were lower, with some birds still
negative. In the group of ducks receiving the monovalent
vaccine, the antibody titers did not rise significantly following
viral challenge. Together with the lack of challenge virus
isolation from pharynx or cloaca, the failure to boost the
antibody response suggests that there was little, if any,
replication of the HPAI challenge virus in these ducks and
that they were protected from both disease and significant
infection.<4 – – <4 4 128 32 32 16
<4 64 128 4 128 64 8 16 16
<4 – – 4 16 16 32 32 16
<4 – – <4 <4 64 32 32 16
<4 64 128 <4 8 64 8 32 8
<4 64 64 8 32 32 32 64 64
<4 – – <4 4 64 16 32 16
<4 32 64 64 32 32
a Time points are indicated relative to challenge on day 0.
b Results from individual ducks are given in the same order as in Table 3.
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As different isolates of the Asian H5N1 HPAI viruses have
been shown to vary in their virulence for different avian and
mammalian species (Govorkova et al., 2005; Nguyen et al.,
2005), it was important to titrate A/Muscovy duck/Vietnam/
453/2004 in the population of ducks that were to be used for
the vaccination trial. Compared to the higher dose groups, the
groups that received the intermediate doses of virus (104.7 and
103.7 EID50) display a delayed onset of morbidity and
mortality, but, interestingly, there were no observations of
nervous signs in these two intermediate dose groups. This
suggests that the spread of virus within the duck and the
pathogenic process is qualitatively different depending on the
size of the infecting dose. However, with the limited number
of birds and of samples taken for virus re-isolation in this
experiment, correlations between the sites or timing of virus
re-isolation and birds with or without nervous signs were not
observed.
The low or undetectable antibody titers in ducks vaccinated
with the bivalent vaccine, which had H5 from strain A/chicken/
Italy/22A/98 demonstrates the importance of matching the
vaccine hemagglutinin antigen to the influenza strain currently
circulating and is the reason why human influenza vaccines are
reformulated each year. Despite the failure to stimulate
significant HI titers, the bivalent vaccine did offer protection
as no ducks showed morbidity or mortality. However, the rise in
antibody titers following challenge is indicative of some virus
replication within these birds.
The hemagglutinin used in the monovalent vaccine was
derived by reverse genetics from A/chicken/Vietnam/C58/04, a
virus closely related to the challenge strain. During construc-
tion, the hemagglutinin was modified by deletion of the
nucleotides encoding four amino acids at the HA1–HA2
cleavage site to create a cleavage site that is similar to that of
non pathogenic viruses (Hatta et al., 2001). This modification
appears not to have affected the immunogenicity of the H5.
Clinical signs and virus isolation occurred earlier in the
vaccination trial than they had in the corresponding group in the
titration experiment. As the ducks were sourced from the same
supplier and were challenged at the same age, there is no obvious
reason for this variation in the timecourse of infection. However,
given the earlier disease progression in the unvaccinated ducks,
it may have been possible that virus could have been detected
before day 4 in the vaccinated birds. However, the failure of the
challenge H5N1 virus to stimulate a secondary antibody
response in the ducks vaccinated with the closely related H5 in
the monovalent vaccine is very strong evidence for minimal, to
no, replication of the challenge virus in those ducks.
In both the titration study and vaccine trial, virus re-isolation
post challenge occurred more frequently from the pharynx of
birds than from the cloaca. However, in some birds virus was
isolated from the cloaca and not the pharynx on particular days.
The optimum time of virus re-isolation was largely, but not
completely, dependent on the challenge dose, and at all doses,
sampling at a single time point would have given an incomplete
picture, demonstrating the danger of assuming that there is noviral shedding after obtaining a negative result at a single time
point.
There have been a number of published trials reporting on
vaccines that provide protective immunity against HPAI.
However, many of those trials have been conducted in SPF
poultry and past experience has shown that vaccine immuno-
genicity, and therefore efficacy, is often lower in conventional
animals than in SPF animals (Heine et al., 1997). While SPF
animals are valuable in eliminating variables during early
studies, it is important to test vaccines intended for eventual
field use, in animals with similar genetics and rearing
conditions. Tian et al. (2005) have also demonstrated that a
vaccine, produced by reverse genetics to express an H5 antigen
from an Asian H5N1 virus, can protect field ducks and geese
from mortality and morbidity, with very reduced shedding of the
challenge virus. However, they did not test whether the
challenge virus boosted the antibody response. When a
Newcastle disease virus expressing H7 was used to vaccinate
non-SPF chickens, 90% of the birds survived a lethal challenge
with HPAI H7N7 virus, but the challenge virus stimulated high
titers of antibody in the surviving birds, suggesting that there
had been significant viral replication, if not shedding (Park et
al., 2006). The apparently less solid protection with the
Newcastle disease vectored vaccine raises the possibility that
other influenza virus gene products have contributed to
protection in the work described here, but differences in the
challenge virus may also have contributed to the different
outcome.
The results presented here demonstrate that a killed
monovalent H5N3 vaccine is able to provide solid protection
in ducks against a challenge with an HPAI virus with a highly
related H5. The absence of any virus re-isolation, tested over
several days, plus the failure to boost the antibody response is
strong evidence that the birds were protected against both
infection and disease. This reassortant vaccine virus can provide
a safe and effective tool for the control of the Asian H5N1
influenza virus in village and commercial ducks, as it will
prevent virus shedding and also will permit the differentiation
between vaccinated and infected birds.
Materials and methods
Viruses and vaccines
A/Muscovy duck/Vietnam/453/2004 H5N1 was obtained
from the Regional Animal Health Centre, Ho Chi Minh City,
Vietnam. This isolate was obtained from diseased ducks and
was passaged twice in SPF chicken eggs (Charles River
Laboratories, Australia). Prior to use, the virus was titrated in
SPF chicken eggs which were incubated at 37 °C for up to 5
days before assessment of allantoic fluid for hemagglutination
activity. The titer was calculated as 108 EID50/ml.
The bivalent vaccine, Poulvac i-AI H5N9, H7N1 was
supplied by Fort dodge Australia Pty. Limited 1 Maitland
Place, Baulkham Hills NSW 2153 Australia, as an inactivated
oil emulsion vaccine formulated with inactivated allantoic
fluids infected with avian influenza virus type A subtypes H5N9
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Italy/1067/H7N1/1999). The monovalent vaccine, Poulvac i-AI
H5N3 RG was derived by reverse genetics by a method similar
to that described by Liu et al. (2003). Briefly, the H5
hemagglutinin from A/chicken/Vietnam/C58/04 was modified
by deletion of twelve nucleotides at the cleavage site between
HA1 and HA2. This gene was combined with N3 from A/Duck/
Germany/1215/73 and the internal genes from A/PR/8/34. Both
vaccines were formulated as water in oil emulsions.
Animals and accommodation
One-day- or six-week-old Pekin ducks of mixed sex were
purchased from a commercial supplier and housed on tiled floors
with access towood shavings andwater for bathing. Theywere fed
commercial rations and also had access to drinking water. A
numbered leg band identified individual ducks. All animal
experimentation was performed with the approval of an
institutional Animal Ethics Committee. Prior to inoculation of
virus, a blood samplewas taken from the jugular vein of each duck.
Titration of virus in ducks
Infectious allantoic fluid from eggs inoculated with A/
Muscovy duck/Vietnam/453/2004 was diluted in ten-fold steps
in sterile phosphate-buffered saline (PBS). Dilutions from 10−1
to 10− 5 were inoculated intraocularly (50 μl per eye),
intranasally (200 μl) and orally (200 μl) into each of five
ducks per dilution, giving a total dose of 106.7 EID50 per duck in
the highest dose group. Following inoculation of virus dilutions
into ducks, samples were back titrated into embryonated eggs to
confirm their titer.
Ducks were monitored twice daily for clinical signs,
particularly depression, inappetence and nervous signs. Ducks
were killed with intravenous barbiturate on welfare grounds if
they demonstrated moderate clinical signs that confirmed
infection (reduced interaction with pen mates, slight head tilt
or twitching). Pharyngeal and cloacal swabs (EUROTUBO
cotton swabs) were taken from all surviving ducks on days 4
and stored at −80 °C in 2 ml PBS+ antibiotics. Blood samples
were taken from the wing vein of each surviving duck at day 10
after challenge. Serum was stored at −20 °C.
All median duck infectious doses (DID50) were calculated
using the Karber formula (Lennette, 1995).
Vaccination trial
The optimal number of ducks per group for the challenge
was assessed to be fifteen, using data from previous work with
the challenge virus, but groups of twenty birds were vaccinated
to account for the normal mortality rate observed in young
birds. The three randomly assigned groups of day-old Pekin
ducks of mixed sexes were each housed in a microbiologically
contained and separate room, under the same conditions used
for the virus titration. Prior to vaccination, ten randomly
selected ducks were screened by c-ELISA which detects
antibodies to all avian influenza A viruses and all ducks werefound to be negative. One group of ducks was inoculated with
PBS; one group was vaccinated with the Poulvac i-AI H5N9,
H7N1 vaccine and the third group with the Poulvac i-AI H5N3
vaccine. As recommended by the manufacturer, the vaccine was
administered subcutaneously in 200 μl high on the neck. The
vaccinated groups were revaccinated at 3 weeks of age, using
500 μl of vaccine delivered by the same route.
Three weeks later, at the time of challenge, only 14
unvaccinated birds remained alive, and the other two groups
were reduced to fifteen, in accordance with welfare require-
ments. Leg bands applied to each bird. Using a 1 ml graduated
syringe, all ducks were inoculated with the challenge virus, A/
Muscovy duck/Vietnam/453/2004. A dose of 101.5 DID50 was
given to each duck, in a total volume of 500 μl, with 200 μl
being delivered to both nares, 200 μl given orally and 100 μl
being delivered to the open eyes.
Ducks were observed twice daily for signs of morbidity or
for mortality. Each duck was bled from the wing vein
immediately prior to challenge and on days 11 and 14 after
challenge to obtain serum for antibody assays. Pharyngeal and
cloacal swabs were taken on days 4 and 7 for virus re-isolation.
Virus re-isolation
Virus isolations were performed according to the Office
International des Epizooties (OIE) Manual (Anon., 2004).
Briefly, swabs were placed in PBS and an aliquot titrated into
embryonated eggs, which were incubated for 5 days at 37 °C
before assay of allantoic fluid for hemagglutinating activity.
Antibody assays
Hemagglutination inhibition antibody titers in serum were
assayed according to the OIE Manual, using A/Muscovy duck/
Vietnam/453/2004 as antigen (Alexander, 2004). This assay
was used to detect antibody specific for the H5 hemagglutinin,
before and after challenge.
For the c-ELISA, A/PR/8/34 H1N1 influenza virus grown in
eggs and diluted in a carbonate buffer was used as antigen. The
test sera were diluted ten-fold in PBS with 0.05% Tween 20 and
1% skim milk powder and added to the antigen-coated plates
together with a monoclonal antibody specific for influenza
nucleoprotein. After incubation and then washing, the bound
monoclonal antibody was detected with sheep anti-murine
immunoglobulin (Silenus Cat. DAH) and TMB substrate
(Sigma Cat. T-2885). The reaction was stopped with sulphuric
acid and the color read at 450 nm. Percent inhibition of binding
of the monoclonal antibody was calculated and less than 40%
inhibition was interpreted as negative.
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